{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:02:29Z","timestamp":1791838949143,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp;amp; Metabol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>GLP\u20101 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns have arisen about their potential link to thyroid cancer. This study investigates the association between thyroid cancer and weight\u2010loss medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A disproportionality analysis was conducted using data from the FDA Adverse Event Reporting System (FAERS) from 2004 to Q1 2024. Reporting odds ratios (RORs) were used to identify associations between thyroid cancer and weight\u2010loss drugs, including anti\u2010diabetic medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant positive associations with thyroid cancer were found for GLP\u20101 receptor agonists: semaglutide (ROR\u2009=\u20097.61, 95% CI: 6.37\u20139.08), dulaglutide (ROR\u2009=\u20093.59, 95% CI: 3.03\u20134.27), liraglutide (ROR\u2009=\u200915.59, 95% CI: 13.94\u201317.44) and tirzepatide (ROR\u2009=\u20092.09, 95% CI: 1.51\u20132.89). A weak inverse association was observed for metformin (ROR\u2009=\u20090.58, 95% CI: 0.36\u20130.93). No significant associations were found for other drugs, such as topiramate, dapagliflozin and insulin glargine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study, based on data from the FAERS database, suggests a potential association between GLP\u20101 receptor agonists and an increased thyroid cancer risk. These findings underscore the importance of further research and continuous safety monitoring when prescribing these medications for obesity management.<\/jats:p><\/jats:sec>","DOI":"10.1002\/edm2.70038","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:54:57Z","timestamp":1741456497000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Exploring Connections Between Weight\u2010Loss Medications and Thyroid Cancer: A Look at the <scp>FDA<\/scp> Adverse Event Reporting System Database"],"prefix":"10.1002","volume":"8","author":[{"given":"Christophe","family":"Abi Zeid Daou","sequence":"first","affiliation":[{"name":"Department of Otolaryngology and Head and Neck Surgery American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Aboul Hosn","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Head and Neck Surgery American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Ghzayel","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Head and Neck Surgery American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Mourad","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Head and Neck Surgery American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","first-page":"9","article-title":"Weight Loss Medication Prescription Prevalence in the Active Component, 2018\u20102023","volume":"31","author":"Lorei N. C.","year":"2024","journal-title":"MSMR"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.01.003"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.12775\/QS.2024.15.52005"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01710-0"},{"key":"e_1_2_10_6_1","unstructured":"A. K.Constantino \u201cOzempic Wegovy Drug Prescriptions Hit 9 Million Surge 300% in Under Three Years \u201d CNBC. 2023 https:\/\/www.cnbc.com\/2023\/09\/27\/ozempic\u2010wegovy\u2010drug\u2010prescriptions\u2010hit\u20109\u2010million.html."},{"key":"e_1_2_10_7_1","unstructured":"Trilliant Health \u201cTrends Shaping the Health Economy: Value for Money \u201dhttps:\/\/www.trillianthealth.com\/reports\/2023\u2010health\u2010economy\u2010trends."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212283"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-010-0013-5"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2020.12.030"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24314"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4346"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15538"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009\u20101272"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15382"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1956"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14060687"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1530\/ec\u201023\u20100257"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.971213"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241241383","article-title":"Exploring the Association Between Weight Loss\u2010Inducing Medications and Multiple Sclerosis: Insights From the FDA Adverse Event Reporting System Database","volume":"17","author":"Shirani A.","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-3291-5.50007-X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084346"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102023\u2010078225"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2028"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.927859"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1148"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0016"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12321"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12926"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae260"},{"key":"e_1_2_10_35_1","article-title":"Effect of GLP\u20101 Receptor Agonists on Prostate Cancer Risk Reduction: A Systematic Review and Meta\u2010Analysis","volume":"2024","author":"Sharma N.","year":"2024","journal-title":"International Urology and Nephrology"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.901559"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183224"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01287-0"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12040574"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.936"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15292"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:46:30Z","timestamp":1746621990000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/edm2.70038"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70038","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70038"}}